SpringWorks Therapeutics Inc (SWTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SpringWorks Therapeutics Inc (SWTX) has a cash flow conversion efficiency ratio of -0.165x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-68.76 Million) by net assets ($417.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SpringWorks Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how SpringWorks Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SpringWorks Therapeutics Inc (SWTX) financial obligations for a breakdown of total debt and financial obligations.
SpringWorks Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SpringWorks Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Box Inc
NYSE:BOX
|
-0.369x |
|
TIZA Information Industry Corporation Inc
SHE:300209
|
-0.016x |
|
Ningbo Sanxing Medical Electric Co Ltd
SHG:601567
|
0.043x |
|
IGO LTD SP.ADR/2
F:IDZ1
|
N/A |
|
Tongyu Communication Inc
SHE:002792
|
0.033x |
|
Beijing Tricolor Technology Co Ltd
SHG:603516
|
0.031x |
|
Asbury Automotive Group Inc
NYSE:ABG
|
0.057x |
|
Runjian Communication Co Ltd Class A
SHE:002929
|
0.083x |
Annual Cash Flow Conversion Efficiency for SpringWorks Therapeutics Inc (2000–2024)
The table below shows the annual cash flow conversion efficiency of SpringWorks Therapeutics Inc from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see SpringWorks Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $481.10 Million | $-175.60 Million | -0.365x | -2.59% |
| 2023-12-31 | $626.22 Million | $-222.79 Million | -0.356x | -22.92% |
| 2022-12-31 | $558.19 Million | $-161.56 Million | -0.289x | +4.39% |
| 2021-12-31 | $422.40 Million | $-127.88 Million | -0.303x | -423.89% |
| 2020-12-31 | $557.06 Million | $-32.19 Million | -0.058x | +60.77% |
| 2019-12-31 | $322.07 Million | $-47.44 Million | -0.147x | -119.40% |
| 2018-12-31 | $-19.37 Million | $-14.71 Million | 0.759x | -10.99% |
| 2017-12-31 | $-2.62 Million | $-2.24 Million | 0.853x | +460.05% |
| 2010-12-31 | $36.81 Million | $5.61 Million | 0.152x | -20.90% |
| 2009-12-31 | $27.15 Million | $5.23 Million | 0.193x | -41.95% |
| 2008-12-31 | $21.41 Million | $7.10 Million | 0.332x | -2.79% |
| 2007-12-31 | $16.69 Million | $5.70 Million | 0.341x | +440.29% |
| 2006-12-31 | $11.85 Million | $748.00K | 0.063x | -74.88% |
| 2005-12-31 | $15.94 Million | $4.01 Million | 0.251x | -4.37% |
| 2004-12-31 | $14.57 Million | $3.83 Million | 0.263x | -49.59% |
| 2001-12-31 | $26.45 Million | $13.79 Million | 0.521x | +561.99% |
| 2000-12-31 | $20.14 Million | $1.59 Million | 0.079x | -- |
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor o… Read more